The effect of FK664, a new cardiovascular drug, on systemic capacitance vessels in anesthetized dogs.
To characterize the cardiovascular effect of FK664, a compound developed for the treatment of heart failure, the mean circulatory pressure (MCP), cardiac output and other parameters were measured in open-chest anesthetized dogs. Milrinone, a cardiotonic agent, and nifedipine, a calcium channel blocker were used as reference substances. Nifedipine (10 micrograms/kg), FK664 (0.1 mg/kg) or milrinone (0.1 mg/kg) given intravenously reduced the total peripheral resistance in a similar extent (35-40%). Whereas nifedipine had no effect on MCP, FK664 produced a significant decrease in MCP. Milrinone caused a minimal decrease in MCP, but not significantly. These results indicate that FK664 dilates the systemic capacitance vessels. This action to reduce the pre-load would be beneficial in the treatment of heart failure.
Sudo
Y
Y
Department of Pharmacology, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Esumi
K
K
D000818:Animals; D001808:Blood Vessels / Q000187:drug effects*; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D007275:Injections, Intravenous; D020105:Milrinone; D009543:Nifedipine / Q000494:pharmacology; D011728:Pyridones / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects
D002316:Cardiotonic Agents; D011728:Pyridones; D011744:Pyrimidinones; C062761:FK 664; D009543:Nifedipine; D020105:Milrinone